 3. Acceptance to be followed for a minimum of three years in the study. Hydroxyurea may be given for other reasons as part of the participants ongoing care, but it will not be given as part of the study SPRING Trial, unless annual TCD reading meets criteria of an elevated TCD measurement based on eligibility criteria for study therapy. 